Study: Daily aspirin use may reduce cancer-related deaths
LONDON — Daily aspirin use may curb cancer-related deaths, according to a new study published in The Lancet.
The study, led by Peter Rothwell of the University of Oxford and colleagues, analyzed data from eight eligible trials — which typically lasted about four years — and included more than 25,000 subjects. Among them, 674 died from cancer.
The researchers found that those who consumed 75 mg of aspirin per day cut their risk of dying from certain cancers by 20%, and found that the prolonged use of aspirin would continue to reduce the death risk of cancer patients. "These findings have implications for guidelines on use of aspirin and for understanding of carcinogenesis and its susceptibility to drug intervention," the study authors said.
But while these conclusions certainly are worth noting, only one-third of the subjects were women, and since the trials on average only lasted four years, the benefits of aspirin consumption may not be properly measured. Additionally, aspirin touts its own risks, including strokes and other complications.
Front-end focus: OTC gets in on the ‘Action’
The phrase coined by Sam Walton — “Stack ’em high and let ’em fly!” — is reverberating throughout Walmart again.
The retailer’s back-to-basics strategy is good news for OTC suppliers, because going back to basics at Walmart also means going back to a broader product selection. Between the resumption of Action Alley and a recommitment to assortment, Walmart already has grown its carrying inventory by 4%, and the company plans to grow its inventory at a rate of half the expected sales lift.
Reverting to Action Alley could spark pantry-loading of the medicine cabinet again. Today, 58% of consumers only purchase an OTC medication when there’s a need, according to a recent SymphonyIRI Group survey. More importantly for Walmart, Action Alley might help reverse the slight decline in OTC dollars and units — Walmart OTC sales were down 0.1% and units were down 2.1% in 2010 versus 2009, SymphonyIRI Group reported.
Action Alley also affords Walmart a ready vehicle to showcase new product launches. “From a supplier’s perspective, you can get your product out there and get market share and trial and penetration much faster through our system than you can anywhere else,” Bill Simon, Walmart U.S. president and CEO, told analysts earlier this year.
Q&A: Synergetic strategy — Scott Verner, Nipro Diagnostics
Drug Store News recently sat down with Scott Verner, president of Nipro Diagnostics, to discuss some of the synergies created by the acquisition of Home Diagnostics by Japan’s Nipro in March.
Drug Store News: How is the new company better positioned in the U.S. market? What are the synergies?
Scott Verner: Not only are we well-positioned for continued growth within the diabetic category, but we [also] are now well-resourced to look beyond our current business toward portfolio expansion. Nipro Diagnostics’ experience in monitoring and management, combined with expanded research and development capabilities, a history of innovative product development [and] strong manufacturing expertise — not to mention monetary resources now available — provide significant opportunity for us to drive new advancements in diabetes health care and beyond.
Given these enhanced resources, we will look at expanding our product portfolio beyond diabetes blood-glucose monitors — potentially even into complementary-device, pharmaceutical, diagnostic and over-the-counter categories — while maintaining our position as the quality/value segment leader.
DSN: What can retailers expect from Nipro in the coming year?
Verner: First and foremost, retailers can expect Nipro to continue to support them just as we have in the past with the highest-quality products, retailer program participation and overall category and business support that has established us as the leader in the quality/value segment.
Our co-branding strategy continues to enable the nation’s leading retailers to leverage their brand names and offer their customers with diabetes the latest blood-glucose monitoring technology offered by our TRUE brand portfolio. … As our retail partners make diabetes care a shopping destination, Nipro hopes to grow with them as we enhance our product offering into categories strategic to our business. We are already investigating adjacent product categories that complement our current product offering, which easily enables us to extend our co-branding strategy.